INTRODUCTION
============

Mesenchymal stem cells (MSCs) are being explored in a large number of clinical trials due to advantages such as multi-differentiation potency, anti-inflammatory properties, modulation of the host immune system, and safety for allogeneic cell transplants ([@b1-bmb-52-689], [@b2-bmb-52-689]). However, populations of MSCs from individuals are limited by a decreasing proliferation potential when propagated for long periods *in vitro* ([@b3-bmb-52-689]). Because iPSCs are highly expandable *in vitro* and can be differentiated into almost any cell type, these cells are frequently discussed in regenerative medicine ([@b1-bmb-52-689], [@b4-bmb-52-689]). As such, iPSC-derived MSCs (iPS-MSCs) may replace MSCs in stem cell therapies ([@b5-bmb-52-689]). Several investigations have shown that iPS-MSCs were comparable to bone marrow (BM)-MSCs in surface marker expression, differentiation potential, and gene expression profile ([@b6-bmb-52-689], [@b7-bmb-52-689]). iPS-MSCs also showed greater regenerative potential, likely due to increased telomerase activity and less senescence than MSCs, leading to superior engraftment and survival after transplantation ([@b7-bmb-52-689]).

Genetic and epigenetic abnormalities in many iPSCs and iPSC-derived MSCs, however, limit their therapeutic use ([@b8-bmb-52-689]). The genomes of iPSCs can contain many anomalies, including aneuploidy, subchromosomal copy number variations, and single nucleotide variations ([@b9-bmb-52-689]--[@b11-bmb-52-689]). Epigenetic variations in iPSCs can be due to incomplete reprogramming or prolonged culture, affecting their ability to differentiate ([@b12-bmb-52-689]). X-chromosome inactivation is reported to vary among iPSCs and can include loss of Xist expression and other repressive chromatin modifications ([@b13-bmb-52-689]).

Mitochondria are the cellular power plants responsible for ATP production ([@b14-bmb-52-689], [@b15-bmb-52-689]). The frequency of mitochondrial DNA (mtDNA) mutations is believed to be at least 10- to 20-fold higher than the frequency of nuclear DNA mutations ([@b16-bmb-52-689]). Individual iPSC clones present with mtDNA mutations transmitted from original blood or fibroblasts, resulting in functional abnormalities ([@b17-bmb-52-689], [@b18-bmb-52-689]).

This study details the establishment of iPS-MSCs from iPSCs derived from dental tissue MSCs and compares the characteristics and mtDNA instability of MSCs versus iPS-MSCs. MtDNA copy number and mutations were analyzed, and mitochondrial function were compared between iPS-MSCs and original MSCs to evaluate mitochondrial function therein ([Fig. 1A](#f1-bmb-52-689){ref-type="fig"}). Although many characteristics of iPS-MSCs are reported to be similar to those of MSCs, the nature of these characteristics remains unclear. One study reported differential expression patterns of mesenchymal and pluripotency genes between iPS-MSCs and MSCs and found that iPS-MSCs were less responsive to differentiation in the mesenchymal lineage ([@b19-bmb-52-689]).

RESULTS AND DISCUSSION
======================

Differentiation of dental tissue-derived iPSCs toward MSCs
----------------------------------------------------------

A total of 6 iPSC lines were generated from dental tissue-derived MSCs, and their pluripotency was characterized ([@b8-bmb-52-689]). All iPSC lines were showed normal PSC morphology ([Fig. 1B](#f1-bmb-52-689){ref-type="fig"}). Random selected three iPSC lines (iPSC 1, iPSC 2 or iPSC 6) were showed positive expression of OCT4 and SSEA4 ([Fig. 1C](#f1-bmb-52-689){ref-type="fig"}). Additionally, the iPSC1 line was formed teratoma containing all three germ layers ([Fig. 1D](#f1-bmb-52-689){ref-type="fig"}).

The selected iPSC1 line was used to test the reported differentiation protocol from iPSCs to MSCs ([@b5-bmb-52-689]--[@b7-bmb-52-689]). The morphology of iPSCs derived from dental-MSCs during differentiation was analyzed to determine whether the shapes formed were similar to those of MSCs. Cells at the edges of iPSC colonies began to change shape on day 7. These cells demonstrated a spindle-like morphology, similar to that of MSCs ([Fig. 1E](#f1-bmb-52-689){ref-type="fig"}) ([@b20-bmb-52-689]). After 3 more weeks of culture, almost all iPS-MSCs presented with an MSC-like morphology ([Fig. 1E](#f1-bmb-52-689){ref-type="fig"}). Next, MSC-specific surface markers (CD markers), including CD44, CD90, and CD105 ([@b21-bmb-52-689]), were assayed. Original MSCs were expressed 100%, 85% and 93%, while iPS1-MSCs were 100%, 46%, and 88% for CD44, CD90, and CD105, respectively. It was reported that reduced expression of CD90 in MSCs enhances their ability to differentiate into MSC lineages ([@b22-bmb-52-689]), therefore, reduced CD90 expression in iPS-MSCs in this study did not adversely affect their ability to differentiate. All cell lines were negative for hematopoietic cell markers CD34 and CD45 ([Fig. 1F](#f1-bmb-52-689){ref-type="fig"}).

Analysis of the expression of pluripotent genes *OCT4* and *NANOG* revealed that their expression was significantly increased in iPSCs over both MSCs and iPS-MSCs ([Fig. 1G](#f1-bmb-52-689){ref-type="fig"}). The expression of *NANOG* was similar in MSCs and iPS-MSCs, whereas the expression of *OCT4* was significantly increased in iPS-MSCs over MSCs, suggesting greater proliferation and differentiation potential as well as inhibition of spontaneous differentiation ([@b23-bmb-52-689]). The levels of expression of mesodermal genes neural cell adhesion molecule (*NCAM*), Msh homeobox 2 (*MSX2*), and platelet-derived growth factor subunit B (*PDGF-*β) ([@b24-bmb-52-689], [@b25-bmb-52-689]), were found to be significantly lower in iPSCs than in MSCs, with those in iPS-MSCs being intermediate. Although expression of mesodermal genes was reduced in iPS-MSCs over MSCs ([@b19-bmb-52-689], [@b26-bmb-52-689]), we considered this difference within acceptable parameters for MSC differentiation and focused on the enhanced expression of these genes in iPS-MSCs compared to iPSCs.

Original MSCs and iPS-MSCs were differentiated into adipocytes, osteocytes, or chondrocytes to investigate their ability to differentiate toward mesenchymal lineages ([Fig. 1H](#f1-bmb-52-689){ref-type="fig"}). Differentiated cells were positive for lineage-specific markers, showing cytoplasmic accumulation of lipid vacuoles, deposition of the calcified extracellular matrix, and formation of proteoglycan. Although we expected iPS-MSCs to show higher differentiation potency due to their increased expression of *OCT4* ([@b27-bmb-52-689]), iPS-MSCs did not have greater mesenchymal differentiation ability than MSCs.

To confirm that iPS-MSCs did not have characteristics of pluripotent stem cells ([@b28-bmb-52-689]), iPS-MSCs were injected into SCID mice, and teratoma formation was assessed ([Fig. 1I](#f1-bmb-52-689){ref-type="fig"}). Injection of iPSCs induced teratoma formation in two of three SCID mice. However, iPS-MSCs did not form teratomas in all injected mice, indicating these cells had lost characteristics of pluripotent stem cells after differentiation.

These results demonstrated that iPS-MSCs showed similar morphology and characteristics to the original MSCs. In particular, CD44 can be used as a specific marker for MSC differentiation ([@b21-bmb-52-689]).

mtDNA mutations and copy number following iPSC reprogramming
------------------------------------------------------------

The mtDNA integrity of iPSCs is an important consideration for therapeutic applications ([@b17-bmb-52-689]). mtDNA mutations were therefore screened in MSCs and individual iPSC lines using Illumina MiSeq sequencing. After selecting variants with at least 2% heteroplasmy levels (the relative levels of mutant to wild-type mtDNA), two mutations were identified, mt4988C\>T in mitochondrially encoded NADH dehydrogenase 2 (*MT-ND2*) gene with 84% heteroplasmy and mt12528G\>A in mitochondrially encoded NADH dehydrogenase 5 (*MT-ND5*) gene with 12% heteroplasmy. Six iPSC lines were generated from MSCs, and seven mutations were identified therein ([Fig. 2A and B](#f2-bmb-52-689){ref-type="fig"}, [Supplementary Table 1](#s1-bmb-52-689){ref-type="supplementary-material"}). All iPSC lines included mtDNA mutations with at least 15% heteroplasmy ([Fig. 2A](#f2-bmb-52-689){ref-type="fig"}), with each iPSC line harboring one to four mutations. Of the seven mutations detected in iPSC lines, two were transmitted from MSCs and detected in several lines ([Fig. 2B](#f2-bmb-52-689){ref-type="fig"}). mt4988C\>T was detected in five iPSC lines with 14% heteroplasmy to homoplasmy (100% mutant mtDNA), and mt12528G\>A was detected in two iPSC lines with 50% heteroplasmy and homoplasmy ([Fig. 2C](#f2-bmb-52-689){ref-type="fig"}). Among the five mutations in iPSC lines not detected in the original MSCs, one was shared by two iPSC lines but varied in heteroplasmy level. The remaining four mutations were unique and found in only one cell line ([Supplementary Table 1](#s1-bmb-52-689){ref-type="supplementary-material"}). Based on our previous report, the novel mutations, detected only iPSC lines, were transmitted from original MSCs, not generated by reprogramming ([@b17-bmb-52-689]). These results were consistent with previous findings, suggesting the need to screen multiple iPSC lines for mutations, as mutation-free cell lines are required for clinical purposes ([@b17-bmb-52-689]).

mtDNA copy number can change during reprogramming. Theoretically, mtDNA copy number of iPSCs could be reduced compared to the original fibroblasts ([@b29-bmb-52-689]), and we compared mtDNA copy number in various MSCs. BM-MSCs showed a significantly lower mtDNA copy number than umbilical cord matrix (UCM)-MSCs or dental-MSCs, whereas UCM-MSCs and dental-MSCs had similar numbers ([Fig. 2E](#f2-bmb-52-689){ref-type="fig"}). When we compared MSCs and iPSCs, we found that copy number was significantly lower in iPSCs (P \< 0.05, [Fig. 2D](#f2-bmb-52-689){ref-type="fig"}) and that the average mtDNA copy number of six iPSC lines was comparable to that of human embryonic stem cells (hESCs) ([Fig. 2E](#f2-bmb-52-689){ref-type="fig"}), suggesting mtDNA copy number may be a physical indicator for reprogramming or differentiation.

Lower mitochondrial respiration in iPS-MSCs
-------------------------------------------

Our results showed that all established iPSC lines harbored mtDNA mutations with over 50% heteroplasmy, which could induce mitochondrial dysfunction ([Fig. 2C](#f2-bmb-52-689){ref-type="fig"}) ([@b17-bmb-52-689]). We further analyzed iPS-MSCs to determine whether mtDNA mutations were transmitted from iPSCs or arose randomly during differentiation. One homoplasmic mutation (mt4988C\>T in *MT-ND2* gene) was detected in iPS1-MSCs derived from an iPSC1 line, which carried the same mutation with iPSC1 ([Fig. 2C and D](#f2-bmb-52-689){ref-type="fig"}, [Supplementary Table 1](#s1-bmb-52-689){ref-type="supplementary-material"}). No novel mutations were detected in iPS1-MSCs, indicating that mtDNA mutations were stable during differentiation ([@b17-bmb-52-689]).

We further evaluated mitochondrial respiration in iPS-MSCs to determine whether the cells displayed adequate metabolic function compared to original MSCs. We performed differentiation of all 6 iPSC lines into MSCs; of these, iPSC5 and iPSC4 went extinct during iPSC maintenance and differentiation, respectively. The highly heteroplasmic non-synonymous mutation in iPSC 5 and rRNA mutation in iPSC4 likely affected cell survival. Differentiated iPS-MSC lines were similar to original MSCs morphologically and showed positive CD44 expression ([Fig. 3A](#f3-bmb-52-689){ref-type="fig"}). We then measured oxygen consumption rates (OCR) for mitochondrial respiration in iPS1-MSCs, iPS2-MSCs, iPS3-MSCs, and iPS6-MSCs by Seashore platform. The OCR tended to be low in all four iPS-MSC lines compared to original MSCs ([Fig. 3B](#f3-bmb-52-689){ref-type="fig"}). These results indicate original MSCs could produce more ATP and overcome more oxidative stress than iPS-MSCs ([@b30-bmb-52-689]).

Although iPS1-MSCs and iPS2-MSCs were harbor fewer mutations, these mutations showed higher heteroplasmy, which could reduce OCR ([@b17-bmb-52-689]). Synonymous mutations can also affect post-transcriptional processing and translation ([@b31-bmb-52-689]), therefore, synonymous mutations in iPS1-MSCs could affect cell metabolism. The iPS3-MSCs, being expected to harbor 2 RNA gene mutations, showed the lowest OCR among all iPS-MSC lines ([Fig. 3B](#f3-bmb-52-689){ref-type="fig"}). We also analyzed the correlation between OCR and heteroplasmy of non-synonymous or RNA gene mutations and found higher heteroplasmy of non-synonymous or RNA gene mutations resulted in lower OCR in iPS-MSC lines ([Fig. 3C](#f3-bmb-52-689){ref-type="fig"}).

Although we could not eliminate all nuclear factors, we found that iPS-MSCs derived from single cloned iPSCs with specific mtDNA mutations demonstrated dysfunctional mitochondrial respiration, suggesting limited therapeutic potential and underscoring the need to screen for mutation-free cell lines.

CONCLUSIONS
===========

In general, the characteristics of iPS-MSCs and MSCs were similar, including cell morphology, expression of MSC-specific CD markers and mesodermal genes, and potency of differentiation into mesenchymal lineages. However, expression levels of CD90 and mesodermal genes were lower, and the expression level of *OCT4* was higher in iPS-MSCs than MSCs. These findings may be associated with incomplete differentiation due to the inadequate expression of reprogramming factors. Fortunately, iPS-MSCs did not form teratomas, reducing the potential for tumor formation following cell transplantation.

The two mtDNA mutations in MSCs were transmitted to several iPSC lines with various heteroplasmy. Some iPSC lines displayed novel mtDNA mutations not detected in MSCs. mtDNA mutations in iPSCs did not change during differentiation to iPS-MSCs, and iPS-MSCs showed no novel mutations. However, iPS-MSCs demonstrated reduced mitochondrial metabolism and lower OCR associated with higher heteroplasmy of non-synonymous or RNA gene mutations.

Taken together, these results were consistent with a previous study ([@b17-bmb-52-689]), confirming the need to screen multiple iPSC lines to detect mutation-free lines for clinical purposes.

MATERIALS AND METHODS
=====================

iPSC reprogramming
------------------

iPSCs were generated from MSCs using an Epi5^TM^ Episomal iPSC Reprogramming Kit (Thermo Fisher) according to manufacturer's instructions. Briefly, plasmid mixtures were electroporated into dental-MSCs with a Neon Transfection System. Transfected cells were seeded onto Geltrex-coated plates (Thermo Fisher). After 3 weeks, colonies were selected and expanded in feeder-free TeSR-E8 medium (Stemcell Technologies).

Immunocytochemistry
-------------------

Fixed iPSCs were permeabilized with 0.05% Triton X-100 for 30 minutes at room temperature (RT). Cells were incubated with primary antibodies OCT4 and SSEA4 (1:100, Stemgent) during an overnight at 4°C. Cells were washed twice and incubated with secondary goat anti-mouse IgG H&L (1:700, Alexa Fluor 488, Abcam), or goat anti-rabbit IgG H&L (1:700, Alexa Fluor 555, Abcam) antibodies for 1 h at RT.

Differentiation into MSCs from iPSCs
------------------------------------

Differentiation of iPSCs toward MSCs was induced as described, with minor modifications ([@b24-bmb-52-689]). Briefly, cells were cultured in ADMEM medium supplemented with 10 μM SB-431542 and 1 ng/μl basic fibroblast growth factor (bFGF) for 7 to 10 days. After 10 days, cells were cultured with ADMEM supplemented with bFGF (5 ng/μl).

Differentiation into mesenchymal lineage
----------------------------------------

Cells were differentiated into mesenchymal lineage as described previously ([@b21-bmb-52-689]). Adipogenesis was induced by DMEM supplemented with 10% FBS, 100 μM indomethacin, 10 μM insulin, and 1 μM dexamethasone. Osteogenesis was induced by DMEM supplemented with 10% FBS, 200 μM ascorbic acid, 10 mM β-glycerophosphate, and 0.1 μM dexamethasone. For chondrogenesis, cells were induced by STEMPRO^®^ Chondrogenesis Differentiation Kit media with 10% supplement.

RT-qPCR analysis
----------------

RNA was extracted using easy-spin^TM^ Total RNA Extraction Kits (iNtRON), and cDNA was synthesized using HisenScript^TM^ RH(−) RT Premix Kits (iNtRON) according to the manufacturer's instructions. qRT-PCR was performed using RealMOD^TM^ Green AP 5X qPCR mix (iNtRON) according to the qRT-PCR program in the manufacturer's protocol with minor modifications.

Cell surface marker analysis
----------------------------

Fixed cells were incubated with fluorescein isothiocyanate (FITC) conjugated mouse anti-CD44, CD45, and CD90 (1:100, BD Pharmingen^TM^) at 4°C for 1 hour, or incubated with unconjugated CD34 and CD105 primary antibodies (1:100, BD Pharmingen^TM^) at 4°C for 1 hour followed by incubation with FITC conjugated secondary antibodies at 4°C for 1 hour. Labeled cells were counted by BD FACS Calibur.

Teratoma formation
------------------

Approximately 1 × 10^6^ cells were suspended in 30% Matrigel in DMEM/F12. Male SCID mice (6 weeks old) were anesthetized with 30 mg/kg Zoletil (Virbac) and 10 mg/kg Rompun (Bayer), followed by the injection into the right femoral region. Six to eight weeks after injection, mice were euthanized, and teratomas were sectioned and histologically analyzed with hematoxylin and eosin (H&E) staining.

Quantification of mitochondrial copy number
-------------------------------------------

mtDNA copy number was determined by a probe-based, single-tube multiplex qPCR assay on the QuantStudio 6 Flex Real-Time PCR System (Life Technologies), as previously described with minor modifications ([@b32-bmb-52-689]). mtDNA copy number was calculated as the ratio of a number of mitochondria to the number of nuclei.

mtDNA sequencing by MiSeq
-------------------------

The whole mtDNA was amplified using two primer sets as previously described ([@b18-bmb-52-689]): mt3163F-GCCTTCCCCCGTAAAT GATA and mt11599R-TGTTTGTCGTAGGCAGATGG; and mt11506F-TCTCAACCCCCTGACAAAAC and mt3259R-TATG CGATTACCGGGCTCT. The DNA was used for library preparation with the Nextera XT DNA Kit (Illumina). Sequencing was performed on the Illumina MiSeq platform, and the data were analyzed using NextGENe software. The remaining process of mtDNA sequencing was as described previously ([@b17-bmb-52-689]).

Seahorse assay
--------------

Mitochondrial respiratory function was measured using an XF Cell MitoStress Test Kit in an XF24 Extracellular Flux Analyzer (Seahorse Biosciences), as described previously ([@b17-bmb-52-689]). Mitochondrial OCR was measured by serial treatment with oligomycin (1.5 μM) for ATP production (oligomycin OCR -- basal OCR), carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP; 1 μM) for maximal respiration and reserve capacity (maximal OCR -- basal OCR), and antimycin A (0.5 μM) and rotenone (0.5 μM) for non-mitochondrial oxygen utilization. Oxygen consumption was normalized to baseline oxygen consumption by measuring cell DNA.

Ethics approval and consent to participate
------------------------------------------

Human dental tissues were obtained from wisdom teeth extracted from patients at the Department of Oral and Maxillofacial Surgery at Gyeongsang National University Hospital under approved medical guidelines (GNUH IRB-2012-09-004). All subjects were provided written informed consent.

Statistical analysis
--------------------

Data were presented as mean ± standard deviation (SD) or ± standard error of the mean (SEM). Results were compared by independent-group *t*-tests for two groups or by ANOVA with Tukey's test for multiple comparisons. Statistical analyses were performed using GraphPad Prism software.
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![Characterization of iPS-MSCs and original MSCs. (A) Experimental design of the study. (B) Morphology of all iPSC lines similar to normal PSC morphology. (C) Characterizations of randomly selected iPSCs. OCT4 and SSEA4 were expressed in iPSC1, 2 and 6. (D) The teratoma formed in the mouse injected with iPSC1. Black arrows indicate three germ layers contained in teratoma. Scale bars = 500 μm. (E) Change in cell morphology to a spindle-like shape during differentiation of iPSC1 to MSCs. Scale bars = 500 μm. (F) Expression of CD markers in MSCs, iPSC1, and iPS1-MSCs. Both of MSCs and iPS1-MSCs were 100% positive in CD44. iPSC1 showed reduced expression of MSC positive markers. Negative MSCs markers, including CD34 and CD45, were expressed at less than 2% in all cell types. (G) Expression of pluripotency and mesodermal related genes in MSCs, iPSC1, and iPS1-MSCs. The level of the pluripotent gene *OCT4* was higher in iPS1-MSCs than MSCs, while expression levels of the mesodermal genes *NCAM*, *MSX2*, and *PDGF-*β were lower in iPSC1 than MSCs. (H) Differentiation of MSCs and iPS1-MSCs into adipogenic, osteogenic, and chondrogenic lineages. (I) Teratoma formation by iPSC1 and iPS1-MSCs. No teratomas were observed in the mice injected with iPS1-MSCs. Black arrows indicate teratoma injection sites. The letters a, b, and c indicate significant (P \< 0.05) differences among MSCs, iPSCs, and iPS-MSCs. Mean ± SEM. MSCs, mesenchymal stem cells; iPSCs, induced pluripotent stem cells; iPS-MSCs, iPSC-derived MSCs; *NCAM*, neural cell adhesion molecule; *MSX2*, Msh homeobox 2; *PDGF*β, platelet-derived growth factor subunit B.](bmb-52-689f1){#f1-bmb-52-689}

![Mitochondrial genome integrity. (A) All iPSC clones harbored meaningful heteroplasmic (\> 15%) mutations. (B) Venn diagram showing two mutations of MSCs shared by iPSC clones. (C) Mutations shared by MSCs and iPSC lines. The mt4988C\>T in MSCs was present in five iPSC lines with various heteroplasmy, and the mt12528G\>A in MSCs were present in two iPSC lines with 50% heteroplasmy and homoplasmy. (D) Stable mtDNA mutation during differentiation into MSCs. One homoplasmic mutation, detected in iPSC1 line, was transmitted to iPS1-MSCs. (E) mtDNA copy number in iPSCs was similar to hESCs. mtDNA copy number of original MSCs was similar in UCM-MSCs and higher than that in BM-MSCs. mtDNA copy number was similar between iPSCs and hESCs. Asterisks indicate statistically significant differences (\*P \< 0.05). Mean ± SEM. mtDNA, mitochondrial DNA; UCM-MSCs, umbilical cord matrix MSCs; BM-MSCs, bone marrow MSCs; hESCs, human embryonic stem cells.](bmb-52-689f2){#f2-bmb-52-689}

![Mitochondrial respiration was lower in iPS-MSCs than in MSCs. (A) Cell morphology and expression of CD44 in iPS-MSC lines. iPS-MSC lines were similar to original MSCs morphologically and displayed positive CD44 expression. The results on expression of CD44 in MSCs and iPS1-MSCs was duplicated in [Fig. 1F](#f1-bmb-52-689){ref-type="fig"}. Scale bars = 250 μm. (B) Lower OCR levels in iPS-MSC lines than in MSCs. Mean ± SM. (C) The correlation of lower OCR to higher heteroplasmy in non-synonymous or RNA gene mutations. Heteroplasmy percentages refer to the sum of heteroplasmy of non-synonymous and RNA gene mutations in each cell line. OCR, oxygen consumption rates.](bmb-52-689f3){#f3-bmb-52-689}
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